Masimo (MASI) Given Daily News Impact Score of -0.01
Media headlines about Masimo (NASDAQ:MASI) have trended somewhat negative recently, AlphaOne Sentiment Analysis reports. The research firm, a unit of Accern, identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Masimo earned a daily sentiment score of -0.01 on AlphaOne’s scale. AlphaOne also gave media coverage about the medical equipment provider an impact score of 58 out of 100, meaning that recent press coverage is somewhat likely to have an effect on the stock’s share price in the next several days.
These are some of the news headlines that may have impacted Alpha One Sentiment Analysis’s scoring:
- Zacks: Brokerages Expect Masimo Co. (MASI) Will Announce Quarterly Sales of $183.61 Million (americanbankingnews.com)
- Global Transcutaneous Oxygen Monitor Industry Overview, Trends, Key Companies Profile and Forecast to 2022 (usfinancialnewstoday.com)
- Short-Squeeze, Earnings Surprise Could Spur Masimo Higher (finance.yahoo.com)
- Apple has a secret team working for treating diabetes (cote-ivoire.com)
- Masimo to Report First Quarter 2017 Financial Results after Market Close on Wednesday, May 3 (finance.yahoo.com)
Shares of Masimo (NASDAQ:MASI) traded up 2.63% during mid-day trading on Thursday, reaching $97.39. The company had a trading volume of 691,174 shares. The company has a market capitalization of $4.91 billion, a price-to-earnings ratio of 17.24 and a beta of 0.98. The stock has a 50 day moving average of $93.70 and a 200-day moving average of $73.72. Masimo has a 52 week low of $41.83 and a 52 week high of $97.62.
Masimo (NASDAQ:MASI) last issued its quarterly earnings data on Tuesday, February 14th. The medical equipment provider reported $0.51 earnings per share for the quarter, missing the consensus estimate of $0.52 by $0.01. The business earned $183.20 million during the quarter, compared to analysts’ expectations of $180.48 million. Masimo had a return on equity of 29.42% and a net margin of 16.31%. The company’s revenue was up 9.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.15 earnings per share. On average, analysts expect that Masimo will post $2.33 earnings per share for the current fiscal year.
Several research firms have recently commented on MASI. Piper Jaffray Companies downgraded Masimo from an “overweight” rating to a “neutral” rating in a research note on Thursday, March 16th. Wedbush reaffirmed an “outperform” rating and issued a $100.00 price objective on shares of Masimo in a research note on Tuesday, April 4th. Raymond James Financial, Inc. downgraded Masimo from an “outperform” rating to a “market perform” rating in a research note on Monday, February 13th. Citigroup Inc downgraded Masimo to a “market perform” rating and set a $60.00 price objective on the stock. in a research note on Monday, February 13th. Finally, Zacks Investment Research raised Masimo from a “hold” rating to a “buy” rating and set a $85.00 price objective on the stock in a research note on Tuesday, February 14th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average price target of $70.00.
In related news, CFO Raad Mark De sold 15,000 shares of the stock in a transaction that occurred on Friday, January 27th. The stock was sold at an average price of $72.50, for a total value of $1,087,500.00. Following the completion of the transaction, the chief financial officer now directly owns 17,660 shares in the company, valued at $1,280,350. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Joe E. Kiani sold 300,000 shares of the stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $80.04, for a total value of $24,012,000.00. Following the completion of the transaction, the chief executive officer now owns 119,241 shares of the company’s stock, valued at $9,544,049.64. The disclosure for this sale can be found here. Insiders sold 531,111 shares of company stock valued at $44,012,761 over the last quarter. 16.60% of the stock is currently owned by company insiders.
Masimo Company Profile
Masimo Corporation is a medical technology company that develops, manufactures and markets a range of non-invasive patient monitoring technologies. The Company’s business is Measure-through Motion and Low Perfusion pulse oximetry monitoring, known as Masimo Signal Extraction Technology (SET) pulse oximetry.
Receive News & Ratings for Masimo Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.